SEC Form 4 · accession 0000886163-16-000168
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John W Kozarich
Director
Period of report
May 2, 2016
Accepted (ET)
May 3, 2016 · 5:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 2, 2016 | S | 800 | $121.45 | D | 43,911 | D | |
| Common StockF1,F3 | May 2, 2016 | S | 200 | $122.04 | D | 43,711 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.98 to $121.90, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.98 to $122.10, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.